drugset
drugset / Trial / NCT03706469

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

NCT03706469 ↗

Phase 1 Completed 16 enrolled Neurocrine Biosciences Takeda · collab
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3 tablet formulation.

Timeline

Start
2018-10-18
Primary completion
2018-12-11
Completion
2018-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Luvadaxistat Small molecule 50 mg Oral
Subject Luvadaxistat Small molecule 600 mg Oral

Indications

No indication recorded.